A study to evaluate hospital admissions and emergency department encounters related to SARS-CoV-2 infections during treatment course of Paxlovid
Latest Information Update: 30 Jun 2022
Price :
$35 *
At a glance
- Drugs Nirmatrelvir+ritonavir (Primary)
- Indications COVID 2019 infections
- Focus Therapeutic Use
- 30 Jun 2022 New trial record
- 24 Jun 2022 Results published in the Morbidity and Mortality Weekly Report